{ "architecture": { "stage_counts": { "advanced": 50, "agentic": 30, "portfolio_candidates": 20, "quantitative": 200, "universe": 2000 }, "stages": [ { "count": 2399, "description": "Discovery securities with valid current feature data.", "key": "valid_source", "label": "Valid Securities" }, { "count": 2000, "description": "Liquidity and history governed universe.", "key": "universe", "label": "Broad Research Universe" }, { "count": 200, "description": "Fast cross-sectional technical screening.", "key": "quantitative", "label": "Quantitative Screen" }, { "count": 50, "description": "Hardened model, uncertainty, risk and data quality.", "key": "advanced", "label": "Advanced Evaluation" }, { "count": 30, "description": "Evidence-governed qualitative assessment.", "key": "agentic", "label": "Agentic Research" }, { "count": 20, "description": "Final monitored candidates, not portfolio weights.", "key": "portfolio_candidates", "label": "Research Candidates" } ] }, "as_of_date": "2026-07-10", "candidates": [ { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Applied Materials, Inc. - Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.7669432918395575, "evidence_count": 12, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 602.5, "median_dollar_volume": 3812425143.5668945, "model_uncertainty": 0.0021351312287324, "primary_evidence_supported": true, "rank": 1, "red_flag_count": 0, "review_status": "primary_evidence_supported", "risk_summary": "The risk assessment is 0.65, based on 20-day volatility 0.066, drawdown resilience 0.767, model uncertainty 0.00214, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.", "scores": { "advanced": 0.8703756484534876, "agentic": 1.187427033523924, "catalyst": 0.5, "confidence": 0.905, "evidence": 1.0, "fundamental": 0.8465909090909092, "macro_fit": 0.5463636363636364, "model": 0.0118882504975243, "quantitative": 1.1498735740259545, "risk": 0.6487272727272727 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_factor_snapshot", "sec_filing_fact" ], "thesis": "AMAT ranks 5/50 in the advanced queue. The hardened model score is 0.01189 and the quantitative score is 1.150. The evidence-grounded fundamental assessment is 0.85; no missing fundamental value was replaced with current or future data.", "ticker": "AMAT" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "BlackBerry Limited Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.6300000190734864, "evidence_count": 12, "exchange": "NYSE", "external_catalyst_evidence": false, "last_price": 10.970000267028809, "median_dollar_volume": 243974397.1579075, "model_uncertainty": 0.0015036319777868, "primary_evidence_supported": true, "rank": 2, "red_flag_count": 0, "review_status": "primary_evidence_supported", "risk_summary": "The risk assessment is 0.58, based on 20-day volatility 0.065, drawdown resilience 0.630, model uncertainty 0.00150, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.", "scores": { "advanced": 0.8248760189616476, "agentic": 0.8186273963242372, "catalyst": 0.5, "confidence": 0.905, "evidence": 1.0, "fundamental": 0.7143939393939394, "macro_fit": 0.4754090909090909, "model": 0.0122275890178884, "quantitative": 1.1638562133782189, "risk": 0.5768181818181819 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_factor_snapshot", "sec_filing_fact" ], "thesis": "BB ranks 8/50 in the advanced queue. The hardened model score is 0.01223 and the quantitative score is 1.164. The evidence-grounded fundamental assessment is 0.71; no missing fundamental value was replaced with current or future data.", "ticker": "BB" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Entravision Communications Corporation Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.7648221289048636, "evidence_count": 4, "exchange": "NYSE", "external_catalyst_evidence": false, "last_price": 11.760000228881836, "median_dollar_volume": 20588257.82532692, "model_uncertainty": 0.0016654713387311, "primary_evidence_supported": false, "rank": 3, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.70, based on 20-day volatility 0.052, drawdown resilience 0.765, model uncertainty 0.00167, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.9832227832086272, "agentic": 0.7977884524493338, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.641, "model": 0.0122441541595447, "quantitative": 1.3946963964908878, "risk": 0.702 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "EVC ranks 2/50 in the advanced queue. The hardened model score is 0.01224 and the quantitative score is 1.395. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "EVC" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Oruka Therapeutics, Inc. - Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.7201204183932429, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 86.79000091552734, "median_dollar_volume": 88123940.09475708, "model_uncertainty": 0.0014685533176374, "primary_evidence_supported": false, "rank": 4, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.66, based on 20-day volatility 0.053, drawdown resilience 0.720, model uncertainty 0.00147, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 1.004748380158452, "agentic": 0.7786409575938249, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.5805, "model": 0.0120926305888657, "quantitative": 1.9003150299454952, "risk": 0.659 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "ORKA ranks 1/50 in the advanced queue. The hardened model score is 0.01209 and the quantitative score is 1.900. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "ORKA" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Advanced Micro Devices, Inc. - Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.7223924891171514, "evidence_count": 11, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 557.8900146484375, "median_dollar_volume": 14991364503.234863, "model_uncertainty": 0.002259877834391, "primary_evidence_supported": true, "rank": 5, "red_flag_count": 0, "review_status": "primary_evidence_supported", "risk_summary": "The risk assessment is 0.64, based on 20-day volatility 0.051, drawdown resilience 0.722, model uncertainty 0.00226, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.", "scores": { "advanced": 0.8149257603554925, "agentic": 0.6218512313013989, "catalyst": 0.5, "confidence": 0.905, "evidence": 1.0, "fundamental": 0.5208333333333334, "macro_fit": 0.5595, "model": 0.0111381849960826, "quantitative": 1.6200444429017669, "risk": 0.641 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_factor_snapshot", "sec_filing_fact" ], "thesis": "AMD ranks 9/50 in the advanced queue. The hardened model score is 0.01114 and the quantitative score is 1.620. The evidence-grounded fundamental assessment is 0.52; no missing fundamental value was replaced with current or future data.", "ticker": "AMD" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Palvella Therapeutics, Inc. - Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.6888904204139026, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 144.75999450683594, "median_dollar_volume": 27605399.83520508, "model_uncertainty": 0.0026613196756465, "primary_evidence_supported": false, "rank": 6, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.59, based on 20-day volatility 0.050, drawdown resilience 0.689, model uncertainty 0.00266, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.922847856901632, "agentic": 0.5574834810585056, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.5880000000000001, "model": 0.0126161859904755, "quantitative": 1.845842949540119, "risk": 0.588 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "PVLA ranks 4/50 in the advanced queue. The hardened model score is 0.01262 and the quantitative score is 1.846. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "PVLA" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Anterix Inc. - Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.7455449812185831, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 100.95999908447266, "median_dollar_volume": 23135325.276374817, "model_uncertainty": 0.0031827463084478, "primary_evidence_supported": false, "rank": 7, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.53, based on 20-day volatility 0.072, drawdown resilience 0.746, model uncertainty 0.00318, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.958824963781724, "agentic": 0.5507869453367615, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.5175000000000001, "model": 0.0131959434979414, "quantitative": 1.8416946610824148, "risk": 0.529 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "ATEX ranks 3/50 in the advanced queue. The hardened model score is 0.01320 and the quantitative score is 1.842. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "ATEX" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Arista Networks, Inc. Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.7167191145363156, "evidence_count": 12, "exchange": "NYSE", "external_catalyst_evidence": false, "last_price": 186.9600067138672, "median_dollar_volume": 1401873914.9772644, "model_uncertainty": 0.002905055506127, "primary_evidence_supported": true, "rank": 8, "red_flag_count": 0, "review_status": "primary_evidence_supported", "risk_summary": "The risk assessment is 0.71, based on 20-day volatility 0.042, drawdown resilience 0.717, model uncertainty 0.00291, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.", "scores": { "advanced": 0.4455538327566958, "agentic": 0.5012282968015138, "catalyst": 0.5, "confidence": 0.905, "evidence": 1.0, "fundamental": 0.903030303030303, "macro_fit": 0.6734545454545454, "model": 0.0088821804971924, "quantitative": 1.9321995058830028, "risk": 0.7149090909090908 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_factor_snapshot", "sec_filing_fact" ], "thesis": "ANET ranks 39/50 in the advanced queue. The hardened model score is 0.00888 and the quantitative score is 1.932. The evidence-grounded fundamental assessment is 0.90; no missing fundamental value was replaced with current or future data.", "ticker": "ANET" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Twist Bioscience Corporation - Common Stock", "data_quality_score": 0.9803829985987856, "drawdown_resilience": 0.6280218113018955, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 90.63999938964844, "median_dollar_volume": 115818881.68239594, "model_uncertainty": 0.0015381194632752, "primary_evidence_supported": false, "rank": 9, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.61, based on 20-day volatility 0.046, drawdown resilience 0.628, model uncertainty 0.00154, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.8312851720736979, "agentic": 0.3880627891081906, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.5955, "model": 0.0120098529019656, "quantitative": 1.6488504693079793, "risk": 0.6090000000000001 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "TWST ranks 7/50 in the advanced queue. The hardened model score is 0.01201 and the quantitative score is 1.649. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "TWST" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "10x Genomics, Inc. - Common Stock", "data_quality_score": 0.9602055114432508, "drawdown_resilience": 0.7197067766146068, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 42.72999954223633, "median_dollar_volume": 90292706.05354308, "model_uncertainty": 0.0033563748911383, "primary_evidence_supported": false, "rank": 10, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.50, based on 20-day volatility 0.053, drawdown resilience 0.720, model uncertainty 0.00336, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.8633564089004861, "agentic": 0.3332008681609311, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.5275, "model": 0.012791354520001, "quantitative": 2.502155799211791, "risk": 0.497 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "TXG ranks 6/50 in the advanced queue. The hardened model score is 0.01279 and the quantitative score is 2.502. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "TXG" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Wayfair Inc. Class A Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.4821503574504224, "evidence_count": 11, "exchange": "NYSE", "external_catalyst_evidence": false, "last_price": 89.2300033569336, "median_dollar_volume": 244901972.3058701, "model_uncertainty": 0.0011723640459475, "primary_evidence_supported": true, "rank": 11, "red_flag_count": 0, "review_status": "primary_evidence_supported", "risk_summary": "The risk assessment is 0.49, based on 20-day volatility 0.049, drawdown resilience 0.482, model uncertainty 0.00117, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.", "scores": { "advanced": 0.7461606226984312, "agentic": 0.3097484880654769, "catalyst": 0.5, "confidence": 0.905, "evidence": 1.0, "fundamental": 0.521969696969697, "macro_fit": 0.4550454545454545, "model": 0.0119028028472755, "quantitative": 1.5081610273386632, "risk": 0.4880909090909091 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_factor_snapshot", "sec_filing_fact" ], "thesis": "W ranks 16/50 in the advanced queue. The hardened model score is 0.01190 and the quantitative score is 1.508. The evidence-grounded fundamental assessment is 0.52; no missing fundamental value was replaced with current or future data.", "ticker": "W" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Kymera Therapeutics, Inc. - Common Stock", "data_quality_score": 0.937972909855208, "drawdown_resilience": 0.7225874568874499, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 119.3499984741211, "median_dollar_volume": 47808525.29296875, "model_uncertainty": 0.0028436689305534, "primary_evidence_supported": false, "rank": 12, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.56, based on 20-day volatility 0.050, drawdown resilience 0.723, model uncertainty 0.00284, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.8131256543273484, "agentic": 0.3059346313049009, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.5875000000000001, "model": 0.0126811692983182, "quantitative": 2.300177083730538, "risk": 0.557 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "KYMR ranks 10/50 in the advanced queue. The hardened model score is 0.01268 and the quantitative score is 2.300. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "KYMR" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Precigen, Inc. - Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.5950095742677072, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 5.320000171661377, "median_dollar_volume": 17563019.536566734, "model_uncertainty": 0.001731890637633, "primary_evidence_supported": false, "rank": 13, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.52, based on 20-day volatility 0.057, drawdown resilience 0.595, model uncertainty 0.00173, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.7962017656244822, "agentic": 0.1815119742762312, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.463, "model": 0.0122150682428887, "quantitative": 1.509382054481535, "risk": 0.522 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "PGEN ranks 13/50 in the advanced queue. The hardened model score is 0.01222 and the quantitative score is 1.509. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "PGEN" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Enliven Therapeutics, Inc. - Common Stock", "data_quality_score": 0.948528724894909, "drawdown_resilience": 0.6316228943272332, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 51.09000015258789, "median_dollar_volume": 36617586.768722534, "model_uncertainty": 0.0020579668945765, "primary_evidence_supported": false, "rank": 14, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.57, based on 20-day volatility 0.047, drawdown resilience 0.632, model uncertainty 0.00206, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.7451250408332172, "agentic": 0.1776482116448512, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.5875000000000001, "model": 0.0122674047690053, "quantitative": 2.003533324480943, "risk": 0.5730000000000001 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "ELVN ranks 17/50 in the advanced queue. The hardened model score is 0.01227 and the quantitative score is 2.004. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "ELVN" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Solid Biosciences Inc. - Common Stock", "data_quality_score": 0.9984119570294256, "drawdown_resilience": 0.5558698686472157, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 10.420000076293944, "median_dollar_volume": 8263546.480226517, "model_uncertainty": 0.0031402936473025, "primary_evidence_supported": false, "rank": 15, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.45, based on 20-day volatility 0.048, drawdown resilience 0.556, model uncertainty 0.00314, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.8018788519326266, "agentic": 0.1615930666574072, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.5105000000000001, "model": 0.012977229922715, "quantitative": 2.039342952955764, "risk": 0.451 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "SLDB ranks 11/50 in the advanced queue. The hardened model score is 0.01298 and the quantitative score is 2.039. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "SLDB" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Definium Therapeutics, Inc. - Common Shares", "data_quality_score": 1.0, "drawdown_resilience": 0.7521127076499925, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 47.06999969482422, "median_dollar_volume": 48055495.41978836, "model_uncertainty": 0.0036328476642275, "primary_evidence_supported": false, "rank": 16, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.48, based on 20-day volatility 0.118, drawdown resilience 0.752, model uncertainty 0.00363, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.8009000947910478, "agentic": 0.1581153628104235, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.456, "model": 0.0125247126159417, "quantitative": 2.1478247672936304, "risk": 0.484 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "DFTX ranks 12/50 in the advanced queue. The hardened model score is 0.01252 and the quantitative score is 2.148. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "DFTX" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Moderna, Inc. - Common Stock", "data_quality_score": 0.9780476412891173, "drawdown_resilience": 0.6449380383982802, "evidence_count": 11, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 68.2699966430664, "median_dollar_volume": 333303243.9689636, "model_uncertainty": 0.0035539082126568, "primary_evidence_supported": true, "rank": 17, "red_flag_count": 0, "review_status": "primary_evidence_supported", "risk_summary": "The risk assessment is 0.48, based on 20-day volatility 0.062, drawdown resilience 0.645, model uncertainty 0.00355, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.", "scores": { "advanced": 0.7894458700331585, "agentic": 0.145352008072962, "catalyst": 0.5, "confidence": 0.905, "evidence": 1.0, "fundamental": 0.3291666666666666, "macro_fit": 0.494, "model": 0.0131790963056223, "quantitative": 1.7850962116980296, "risk": 0.48 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_factor_snapshot", "sec_filing_fact" ], "thesis": "MRNA ranks 14/50 in the advanced queue. The hardened model score is 0.01318 and the quantitative score is 1.785. The evidence-grounded fundamental assessment is 0.33; no missing fundamental value was replaced with current or future data.", "ticker": "MRNA" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "MillerKnoll, Inc. - Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.6219740288365406, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 20.15999984741211, "median_dollar_volume": 11863481.61907196, "model_uncertainty": 0.0023024019105492, "primary_evidence_supported": false, "rank": 18, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.67, based on 20-day volatility 0.040, drawdown resilience 0.622, model uncertainty 0.00230, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.6592278153352287, "agentic": 0.1090172591763794, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.661, "model": 0.0110063677775719, "quantitative": 1.7623641323837282, "risk": 0.666 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "MLKN ranks 26/50 in the advanced queue. The hardened model score is 0.01101 and the quantitative score is 1.762. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "MLKN" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "Bio-Techne Corp - Common Stock", "data_quality_score": 1.0, "drawdown_resilience": 0.6074286683609823, "evidence_count": 4, "exchange": "NASDAQ", "external_catalyst_evidence": false, "last_price": 71.30000305175781, "median_dollar_volume": 148170112.66441345, "model_uncertainty": 0.0022132495567193, "primary_evidence_supported": false, "rank": 19, "red_flag_count": 1, "review_status": "internal_evidence_only", "risk_summary": "The risk assessment is 0.57, based on 20-day volatility 0.048, drawdown resilience 0.607, model uncertainty 0.00221, data coverage, and available point-in-time leverage evidence. Red-flag count is 1.", "scores": { "advanced": 0.7296032074972351, "agentic": 0.1059560071414663, "catalyst": 0.5, "confidence": 0.62, "evidence": 0.78, "fundamental": 0.5, "macro_fit": 0.516, "model": 0.0112685953018852, "quantitative": 2.0910467347667097, "risk": 0.5680000000000001 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_coverage_gap" ], "thesis": "TECH ranks 20/50 in the advanced queue. The hardened model score is 0.01127 and the quantitative score is 2.091. The evidence-grounded fundamental assessment is 0.50; no missing fundamental value was replaced with current or future data.", "ticker": "TECH" }, { "catalyst_summary": "No accepted company-specific catalyst source is present in the governed research packet. The catalyst score therefore remains neutral at 0.50 and is not inferred from price momentum, model rank, or market behavior.", "company_name": "GE Vernova Inc. Common Stock", "data_quality_score": 0.8535263895375993, "drawdown_resilience": 0.7542995796599307, "evidence_count": 12, "exchange": "NYSE", "external_catalyst_evidence": false, "last_price": 1091.5699462890625, "median_dollar_volume": 2685021446.044922, "model_uncertainty": 0.0023016158623921, "primary_evidence_supported": true, "rank": 20, "red_flag_count": 0, "review_status": "primary_evidence_supported", "risk_summary": "The risk assessment is 0.67, based on 20-day volatility 0.042, drawdown resilience 0.754, model uncertainty 0.00230, data coverage, and available point-in-time leverage evidence. Red-flag count is 0.", "scores": { "advanced": 0.432393111768985, "agentic": 0.0980571576304583, "catalyst": 0.5, "confidence": 0.905, "evidence": 1.0, "fundamental": 0.6503787878787879, "macro_fit": 0.6911818181818182, "model": 0.0113956604329018, "quantitative": 1.4409318157964162, "risk": 0.6703636363636364 }, "security_type": "COMMON_STOCK", "source_types": [ "salarium_macro_state", "salarium_market_snapshot", "salarium_model", "sec_factor_snapshot", "sec_filing_fact" ], "thesis": "GEV ranks 40/50 in the advanced queue. The hardened model score is 0.01140 and the quantitative score is 1.441. The evidence-grounded fundamental assessment is 0.65; no missing fundamental value was replaced with current or future data.", "ticker": "GEV" } ], "disclosures": [ "These are research candidates, not portfolio weights, trade instructions, or investment advice.", "The current qualitative layer is an internal-evidence baseline.", "Company-specific catalysts were not asserted without accepted external catalyst evidence.", "Neutral fundamental assessments indicate insufficient primary evidence, not a positive or negative fundamental conclusion.", "Historical model research remains subject to the documented survivorship-bias limitation." ], "evidence_summary": { "candidate_count": 20, "confidence_cap_without_primary": 0.65, "external_catalyst_evidence": 0, "fundamental_neutral_assessments": 15, "high_confidence_candidates": 7, "internal_evidence_only": 13, "neutral_catalyst_assessments": 20, "primary_evidence_supported": 7, "red_flag_free_candidates": 7 }, "generated_at_utc": "2026-08-11T04:16:51.549104+00:00", "provenance": { "git": { "branch": "phase4-macro-walkforward-risk-controls", "commit": "e3db28624ec0de9e1dac7e1f8387ff0cbd2367c7", "dirty": false }, "run_created_at_utc": "2026-08-11T04:01:00.996159+00:00", "run_id": "20260811T040100888187Z", "source_manifest": "results/candidate_funnel/20260811T040100888187Z/manifest.json" }, "schema_version": "1.0", "system": { "name": "Salarium", "status": "complete_internal_evidence_baseline", "surface": "Candidate Intelligence Funnel" } }